Global Access to Essential Medicines for Childhood Cancer: A Cross-Sectional Survey
Journal of Global Oncology · 2018-12 · (4) · 1-11
DOI: 10.1200/jgo.18.00150 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift Journal of Global Oncology, 2018-12. Verfasst von Phillip Cohen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Phillip Cohen, Children's Hospital of Philadelphia, Philadelphia, PA; Phillip Cohen, Centre for Global Health, Trinity College Dublin, Dublin, Irelan…. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Purpose
Global data mapping access to essential chemotherapeutics for pediatric cancer are scarce. We report a survey of international pediatric cancer care providers’ access to these medicines.
Methods
A Web-based survey was sent to pediatric oncologists registered on the Cure4Kids Web portal. We queried chemotherapeutics in the WHO Essential Medicines List for Children, from which the average proportional availability was summarized as each country’s access score. In addition, we examined availability of drug packages defined by the WHO-sanctioned Expert Committee for eight pediatric cancers. We undertook a sensitivity analysis investigating how regimen access would change if the cytotoxics specified in recent agreements between the Clinton Health Access Initiative, American Cancer Society, and pharmaceutical companies were universally available.
Results
There were significant ( P < .001) differences in the median access scores between World Bank income groups, and 42.9% of respondents from low-income and lower middle–income countries reported suboptimal access scores. Our disease-based analysis revealed that 42.1% of patients in low-income and lower middle–income countries lacked full access to chemotherapy packages. Guaranteed availability of the cytotoxics specified in the Clinton Health Access Initiative/American Cancer Society agreements was projected to increase this regimen-based access by 1.6%, although including four additional chemotherapeutics would further increase coverage by 13.9%.
Conclusion
This study is the first, to our knowledge, to assess worldwide variation in practical access to pediatric chemotherapy. Although mapping the proportion of available chemotherapeutics is informative, we also developed a meaningful estimate of access using disease-specific drug packages. These data provide an important baseline for continued monitoring and can aid in planning adaptive treatment guidelines that consider the trade-offs between access and outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Phillip Cohen, Children's Hospital of Philadelphia, Philadelphia, PA; Phillip Cohen, Centre for Global Health, Trinity College Dublin, Dublin, Ireland; and Paola Friedrich, Catherine Lam, Sima Jeha, Monika L. Metzger, I…
Zitieren
APA
Cohen, P., Friedrich, P., Lam, C., Jeha, S., Metzger, M. L., Qaddoumi, I., Naidu, P., Faughnan, L., Rodriguez-Galindo, C., & Bhakta, N. (2018). Global Access to Essential Medicines for Childhood Cancer: A Cross-Sectional Survey. Journal of Global Oncology, 1-11. https://doi.org/10.1200/jgo.18.00150
Vancouver
Cohen P, Friedrich P, Lam C, Jeha S, Metzger ML, Qaddoumi I, et al. Global Access to Essential Medicines for Childhood Cancer: A Cross-Sectional Survey. Journal of Global Oncology. 2018:1-11. doi:10.1200/jgo.18.00150
BibTeX
@article{Cohen2018,
author = {Cohen, Phillip and Friedrich, Paola and Lam, Catherine and Jeha, Sima and Metzger, Monika L and Qaddoumi, Ibraham and Naidu, Paula and Faughnan, Lane and Rodriguez-Galindo, Carlos and Bhakta, Nickhill},
title = {Global Access to Essential Medicines for Childhood Cancer: A Cross-Sectional Survey},
journal = {Journal of Global Oncology},
year = {2018},
number = {4},
pages = {1--11},
doi = {10.1200/jgo.18.00150}
}
EUVIMED